Panitumumab, the first fully human antibody that targets the EGFR, significantly improved the progression-free survival of patients with metastatic colorectal cancer (CRC) in a phase III trial.

Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy could become the new standard of care, according to a new City of Hope ...

Panitumumab targets the epithelial growth ... "Instead of exposing the patient to an invasive biopsy, they can go and get an ...

BMC Clin Pharmacol. 2011;11(17):1-10. The fully human nature of panitumumab was expected to decrease the rate of immunogenicity compared with therapeutic antibodies containing nonhuman coding ...